Oral administration of a KMO inhibitor to AD model mice increased KYNA levels in the brain and improved AD-like behavioral phenotypes [114], indicating the involvement of KYN metabolic abnormalities in AD pathology. The gene discussed is KMO; the disease is Alzheimer disease.